Long-term safety results from a Phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis

Publication date: Available online 15 September 2018

Source: Journal of the American Academy of Dermatology

Author(s): Mark G. Lebwohl, Jeffrey L. Sugarman, Linda Stein Gold, David M. Pariser, Tina Lin, Radhakrishnan Pillai, Gina Martin, Susan Harris, Robert Israel

https://ift.tt/2pexr4N